drugset
drugset / Trial / NCT01951599

To Determine the Relative Bioavailability of Different Formulations of AZD9291 and the Effect of Food.

NCT01951599 ↗

Phase 1 Completed 35 enrolled AstraZeneca
NaSingle-groupOpen-labelBasic science

Summary

To determine the relative bioavailability of different oral formulations of AZD9291 and the effect of food in healthy volunteers.

Timeline

Start
2013-10-09
Primary completion
2014-06-04
Completion
2014-06-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Osimertinib Small molecule 20 mg Oral

Indications

No indication recorded.